

Document No.	HAEM-W-776	Version No. Issue Date	4 28/02/2022
--------------	------------	---------------------------	-----------------



Haematological Malignancy Diagnostic Service Request Form

HMDS, Haematology/Biochemistry Combined Reception
Western General Hospital, Crewe Road South, Edinburgh EH4 2XU
Tel. 0131-537-2374 email: hmds.lothian@nhslothian.scot.nhs.uk

website: <https://edinburghlabmed.co.uk/Specialities/GeneScience/HMDS/Pages/default>

REQUESTOR DETAILS:

Requesting Consultant/GP:			
Hospital/Site			
Contact telephone/page:		Destination for report:	

PATIENT DETAILS:

Surname:		Forename:		
CHI (or Date of Birth):		Gender:	M / F	
Address :				
Specimen Ref. No.		Specimen type:	PB <input type="checkbox"/> BM <input type="checkbox"/> FFPE <input type="checkbox"/>	
Sample collection date/time		Priority:	Routine <input type="checkbox"/> Urgent <input type="checkbox"/>	
Clinical details:				

Please tick test requested

<p>CML t(9;22) BCR::ABL1</p> <p><input type="checkbox"/> Qualitative diagnostic sample</p> <p><input type="checkbox"/> Quantitative BCR::ABL1 (follow up) Specify P190 or P210 (please circle)</p> <p><input type="checkbox"/> BCR::ABL1 kinase domain mutation analysis</p> <p><i>10-15 mls blood (EDTA)</i></p>	<p>Lymphoma/mature lymphoid malignancies</p> <p><input type="checkbox"/> T cell clonality studies</p> <p><input type="checkbox"/> B cell clonality studies</p> <p><input type="checkbox"/> MYD88 p.L265P</p> <p><input type="checkbox"/> BRAF p.V600E</p> <p><i>5 mls blood (EDTA) or bone marrow specimen or FFPE</i></p>
<p>Acute myeloid leukaemia</p> <p><input type="checkbox"/> t(15;17) PML::RARA</p> <p><input type="checkbox"/> t(8;21) RUNX1::RUNX1T1</p> <p><input type="checkbox"/> Inv (16) CBFβ::MYH11</p> <p><input type="checkbox"/> t(9;22) BCR::ABL1</p> <p><input type="checkbox"/> FLT3 ITD/TKD mutation</p> <p><input type="checkbox"/> NPM1 mutation</p> <p><input type="checkbox"/> KMT2A (MLL fusions)</p> <p><input type="checkbox"/> KIT p.D816V</p> <p><input type="checkbox"/> Myeloid next generation sequencing</p> <p>Diagnostic sample <input type="checkbox"/></p> <p>Follow up sample <input type="checkbox"/></p> <p><i>10-15 mls blood (EDTA) or bone marrow specimen</i></p>	<p>Acute lymphoblastic leukaemia</p> <p><input type="checkbox"/> t(9;22) BCR::ABL1</p> <p><input type="checkbox"/> t(12;21)ETV6::RUNX1</p> <p><input type="checkbox"/> t(1;19) E2A::PBX1</p> <p><input type="checkbox"/> KMT2A (MLL fusions)</p> <p><input type="checkbox"/> IG/TCR MRD</p> <p>Diagnostic sample <input type="checkbox"/></p> <p>Follow up sample <input type="checkbox"/></p> <p><i>10-15 mls blood (EDTA) or bone marrow specimen</i></p>
<p>MPN</p> <p><input type="checkbox"/> KIT p.D816V</p> <p><input type="checkbox"/> FIP1L1::PDGFRA fusion</p> <p><i>10-15 mls blood (EDTA) or bone marrow specimen</i></p>	<p>CLL</p> <p><input type="checkbox"/> TP53</p> <p><input type="checkbox"/> IGHV mutation status</p> <p><i>5 mls blood (EDTA) or bone marrow specimen</i></p>

Other tests [For NGS other than AML, please complete a myeloid NGS request form]

Document No.	HAEM-W-776	Version No. Issue Date	4 28/02/2022
--------------	------------	---------------------------	-----------------

Address for delivery:

HMDS, Western General
Hospital,
Haematology/Biochemistry
Combined Reception
Immunophenotyping
Laboratory, Crewe Road South,
Edinburgh EH4 2XU

Phone: 0131 5372374 / 0131 5371145
Internal: 32374 / 31145

Arrange for immediate transport to the laboratory.

It is your responsibility to ensure that samples are packaged to comply with the European Agreement concerning the International Carriage of Dangerous Goods by Road (ADR, 2017) at https://www.unece.org/fileadmin/DAM/trans/danger/publi/adr/adr2017/ADR2017e_web.pdf

Fold along the dotted lines and place in sample bag with address facing outwards

Consent

In accordance with the requirements of the Human Tissue (Scotland) Act 2006, **it is the responsibility of the referring clinician to ensure that appropriate informed consent has been obtained before any testing is undertaken.** The laboratory must be informed of any restrictions to this consent (e.g. storage of samples).

Unless otherwise informed, the laboratory assumes that all appropriate consent has been obtained from the patient for the tests requested and for storage of the derived DNA and RNA for future use both in assisting further testing (if required) and in the development of future diagnostic tests. If in doubt, contact a member of the HMDS team to discuss.

Incomplete or illegible forms may cause delay or rejection of samples

FOR LABORATORY USE ONLY			
Received by		Volume received	
Date/time received		Lab number	

Authority For Issue: Louise Gilroy	Page 2 of 2
Document printed from Q-pulse07/03/2022 13:34 by Bench, Anthony	

This is a controlled document: This copy is valid on day of print only, after which the user must ensure that this is the correct version by comparing against the current document details in Q-Pulse